The relationship of increased NFκB activation with decreased STAT3 phosphorylation caused by ruxolitinib (Figure 2D) suggested JAK-activating cytokines in the cultures might be inhibiting TLR-signaling in CLL cells. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.